Stock Watch: Cancer Combination Therapies Face Rising Bar
Additive Improvements Are Getting Harder To Demonstrate
Executive Summary
Improving efficacy by combining drugs has been a mainstay of cancer therapy but adding new targeted drugs together based on very early-stage data is not working out, especially when one of the drugs is barely active on its own.
You may also be interested in...
GSK Files Its BCMA Drug In Multiple Myeloma
GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.
Stock Watch: Rare Diseases Beget Rare Profitability
Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?
Stock Watch: Academia’s Undiscovered Drug Developments
It is easy for university researchers to criticize the pharmaceutical sector’s R&D productivity when they ignore the contributions of all the drugs that have been approved, and all those that have been rejected.